News

Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has

The company’s announcement also included the issuance of $22m in shares upon conversion of debt into equity Participants included ARCH Venture Partners, the Wellcome Trust, Steven Paul M.D.,

Acebilustat is a small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the crucial enzyme in the production of the potent inflammatory mediator Leukotriene B4 (LTB4). The anti-inflammatory drug

The core component of the program will be to conduct a 24-week Phase 2 trial of the Company’s lead product candidate, GKT831, in patients with IPF. The academic

The new location joins Sydney and Brisbane as the third Australian hub and solidifies the company’s position as the leader in Australia for clinical trial supply chain solutions.

The marketing authorization has been granted for Xeljanz10 mg twice-daily (BID) for at least eight weeks, followed by Xeljanz 5mg BID or 10 mg BID, to treat adult

Included in the acquisition are branded topical prescription treatments for acne, fungal skin infections and rosacea, along with a variety of topical steroids, which had an annual turnover

ZIKV-IG was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in December 2017. Emergent BioSolutions senior vice president and antibody therapeutics business unit head

Myalepta has been approved as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized